ImmunityBio, Inc. (IBRX) stock analysis

IBRX · ImmunityBio, Inc.

Latest recorded price: USD 5.98

Sector and industry: Healthcare · Biotechnology

Fiscal 2025 figures: revenue growth 678.6%, free cash flow margin -272.6%. The model flags 2 risk signals for this company (1 high severity).

Similar companies in Healthcare